8-K: Humana Exceeds Q3 Expectations, Raises Full-Year EPS Guidance

Humana reported strong third-quarter results, exceeding expectations and raising its full-year adjusted EPS guidance to at least $16.00.

Summary

• Humana's third-quarter 2024 adjusted earnings per share (EPS) reached $4.16, surpassing both internal expectations and consensus estimates.
• The company's performance was driven by higher-than-anticipated revenue in the Medicare Advantage (MA) business and strong results in CenterWell Primary Care.
• Humana has increased its full-year 2024 individual MA membership growth guidance by 40,000 to approximately 265,000, representing about 5% year-over-year growth.
• The Insurance segment benefit ratio was in line with expectations for the third quarter, with higher member risk scores and in-line medical costs in MA, offset by higher Medicaid costs.
• The company reaffirmed its full-year Insurance segment benefit ratio guidance of approximately 90%.
• Humana now expects its full-year 2024 adjusted EPS to be at least $16.00, up from the previous guidance of approximately $16.00.
• The company anticipates the fourth quarter Insurance segment benefit ratio to be between 91.5% and 92%, with the consolidated benefit ratio approximately 40 basis points lower.
• CenterWell Primary Care exceeded expectations due to higher patient volume and revenue, along with favorable prior-year development.
• Humana expects to serve 350,000 to 360,000 patients in its Primary Care Organization by year-end, representing a year-over-year growth of 55,000 to 65,000 patients.
• The company anticipates operating approximately 340 centers by year-end, a 15% year-over-year increase.
• Humana's Medicaid membership growth is now expected to be approximately 200,000 for the full year, down from the previous estimate of 250,000 due to a delay in Kentucky.

Sentiment

Score: 7

Explanation: The document conveys a generally positive sentiment due to the better-than-expected financial results and increased guidance. However, there are some concerns about Medicaid costs, the 2025 Star Ratings, and the anticipated decline in individual MA membership in 2025, which temper the overall optimism.

Positives

• Third-quarter financial results exceeded expectations, driven by strong performance in Medicare Advantage and CenterWell Primary Care.
• Humana is experiencing better-than-expected retention and non-DSNP sales in its individual MA business.
• The company is seeing strong patient growth in its de novo and wholly-owned primary care centers.
• Humana is expanding its CenterWell Home Health footprint through the acquisition of Intrepid.
• The company is making strategic investments to support long-term value creation, including strengthening its Stars program.
• Humana is ranked No. 1 among health insurers for customer experience by Forrester for the fourth consecutive year.
• Humana's Value plan for prescription drug plans is positioned competitively and is designed to be attractive to cost-conscious consumers.

Negatives

• Medicaid medical costs were higher than anticipated in the third quarter, particularly in newly implemented states.
• Humana anticipates a decline of a few hundred thousand individual MA members in 2025, primarily due to plan and county exits.
• The company is facing challenges related to the 2025 Medicare Advantage Star Ratings, leading to a lawsuit against CMS.
• Humana's Medicaid membership growth is now expected to be approximately 200,000 for the full year, down from the previous estimate of 250,000 due to a delay in Kentucky.
• The company acknowledges there is now more risk in its ability to fully achieve its individual MA margin target of at least 3 percent by 2027 due to the 2025 MA Star results.

Risks

• Humana faces risks related to the design and pricing of its products, and the ability to manage medical costs effectively.
• The company's profitability could be adversely affected if its estimates of benefit expenses are inadequate.
• Failure to maintain or improve Star ratings could negatively impact revenues and operating results.
• Cybersecurity attacks and data breaches could disrupt operations and lead to the dissemination of sensitive information.
• Legal actions and disputes could result in substantial monetary damages or changes in business practices.
• Changes to government regulations and payment rates could increase costs and affect profitability.
• The company's ability to obtain funds from certain licensed subsidiaries is restricted by state insurance regulations.
• Downgrades in Humana's debt ratings could adversely affect its business and financial condition.
• Volatility in the securities and credit markets may negatively impact the value of the investment portfolio.

Future Outlook

Humana expects 2025 adjusted EPS to be at least in line with final 2024 results, inclusive of additional investments, and assuming 2025 individual MA membership growth is in line with current expectations. The company anticipates a decline of a few hundred thousand individual MA members in 2025, primarily due to plan and county exits. Humana is also focused on continued advancement of its integrated health strategy, which is expected to drive better patient outcomes and earnings growth over time.

Management Comments

• Jim Rechtin, President and CEO, stated that third-quarter financial results exceeded expectations.
• Susan Diamond, CFO, highlighted the increase in full-year adjusted EPS guidance to at least $16.00.
• Management emphasized the company's commitment to achieving its individual MA margin target of at least 3 percent, while acknowledging increased risk due to the 2025 MA Star results.
• Management noted that the company is evaluating additional investments in 2025 to support operational excellence and position the company for long-term success.
• Management expressed optimism regarding the positive prospects for MA and VBC, with Humana well positioned to compete as an industry leader.

Industry Context

Humana's results and outlook are set against a backdrop of a dynamic healthcare industry, with ongoing regulatory changes and evolving cost trends. The company's focus on Medicare Advantage and value-based care aligns with broader industry trends, as these models are increasingly popular with beneficiaries and are seen as a way to improve health outcomes and reduce costs. The company's expansion in Medicaid also reflects a growing trend of integrating Medicare and Medicaid to serve the D-SNP population.

Comparison to Industry Standards

• Humana's individual MA membership growth of approximately 5% year-over-year is slightly below the industry growth expectations of approximately 6%.
• Humana's lawsuit against CMS regarding the 2025 Star Ratings highlights a broader industry concern about the transparency and accuracy of the rating system.
• The company's focus on value-based care and senior-focused primary care aligns with industry best practices, as evidenced by the study published in Health Affairs.
• Humana's expansion in the Medicaid market is consistent with other large health insurers seeking to diversify their revenue streams and serve a broader population.
• The company's investment in digital tools and broker support reflects a growing trend in the industry to enhance the customer experience and improve sales effectiveness.
• Humana's performance in the CenterWell segment is comparable to other healthcare providers that are expanding their primary care and home health services.

Legal Proceedings

• Humana has filed a lawsuit related to the 2025 Medicare Advantage Star Ratings results, challenging the lack of transparency into the data underlying the ratings and CMS scoring of specific call center testing.

Stakeholder Impact

• Shareholders will likely react positively to the increased EPS guidance and strong third-quarter results.
• Employees may be impacted by the company's ongoing value creation initiatives and strategic investments.
• Customers will benefit from the company's focus on improving customer experience and providing high-quality, affordable healthcare coverage.
• Providers will be impacted by the company's value-based care initiatives and its expansion of the CenterWell platform.
• Suppliers and creditors will be affected by the company's financial performance and its ability to manage costs effectively.

Next Steps

• Humana will continue to focus on strengthening its Stars program and improving performance across key measures.
• The company will provide formal 2025 guidance on its fourth-quarter 2024 earnings call early next year.
• Humana is targeting an Investor Day in May 2025 to provide a fulsome update on its annual strategic planning process.
• The company will continue to evaluate additional investments in 2025 to support operational excellence and profitable membership growth.
• Humana will continue to work closely with state and industry partners to ensure Medicaid rates reflect the acuity level of members and emerging cost trends.

Key Dates

Keywords

Medicare Advantage, Medicaid, CenterWell, Primary Care, Home Health, EPS, Star Ratings, Membership Growth, Benefit Ratio, Healthcare, Insurance